Autologous SUPLEXA is under clinical development by Alloplex Biotherapeutics and currently in Phase I for Refractory Multiple Myeloma.

Autologous SUPLEXA is under clinical development by Alloplex Biotherapeutics and currently in Phase I for Lymphoma.

In a Seoul laboratory, scientists are exploring an unexpected avenue to meet the needs of canine blood transfusions. Their ...

DNA was obtained from the peripheral blood and interrogated for mitochondrial DNA copy number (mtDNAcn). Peripheral blood mononuclear cells isolated from peripheral blood were examined for respiratory ...

Oxygen treatment decreased cell activity but failed to enhance metabolic function in patients with diabetes. Researchers at ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) ...

“Philanthropic support plays a critical role in accelerating the development of these new, transformative treatments,” said ...

Cold feet and hands may be due to a lot of factors, including poor circulation. Wearing warm clothes and staying active can ...

In February 2024, the FDA approved Onivyde (irinotecan liposome) with oxaliplatin, fluorouracil and leucovorin for the ...

Researchers are studying overactive cells linked to type 2 diabetes and cardiovascular disorders, aiming to develop targeted ...

When Allie Reimold boarded Flight 2223 in Houston a week ago, she didn’t expect to see the pilot whose life she had saved.

Unique cell-impermeable1 design extends life-saving treatment for dialysis patientsMerit to host a WRAPSODY informational call on January 28, ...